Novo Nordisk Joins the Pack with Smart-Insulin Acquisition of Ziylo for US$800 M
By Michelle Liu
Pharma Deals Review: Vol 2018 Issue 8 (Table of Contents)
Published: 31 Aug-2018
DOI: 10.3833/pdr.v2018.i8.2353 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Following the likes of Eli Lilly and Sanofi into the smart insulin field, Novo Nordisk has acquired UK group Ziylo and its glucose binding molecule platform to create glucose responsive insulins in a deal potentially worth US$800 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS